Equities research analysts expect Catalyst Biosciences Inc (NASDAQ:CBIO) to report earnings of ($0.59) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences posted earnings per share of ($0.96) during the same quarter last year, which indicates a positive year-over-year growth rate of 38.5%. The business is expected to issue its next quarterly earnings results on Thursday, March 7th.
On average, analysts expect that Catalyst Biosciences will report full-year earnings of ($2.27) per share for the current year. For the next financial year, analysts expect that the company will report earnings of ($2.86) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Catalyst Biosciences.
Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings results on Friday, November 2nd. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.05). Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 22.67%.
Separately, Zacks Investment Research lowered shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $19.83.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its stake in Catalyst Biosciences by 148.3% during the first quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 5,340 shares in the last quarter. Kalos Management Inc. bought a new position in shares of Catalyst Biosciences in the second quarter valued at $244,000. Quantitative Systematic Strategies LLC bought a new position in shares of Catalyst Biosciences in the second quarter valued at $120,000. Rhumbline Advisers bought a new position in shares of Catalyst Biosciences in the second quarter valued at $136,000. Finally, Northern Trust Corp lifted its stake in shares of Catalyst Biosciences by 91.0% in the first quarter. Northern Trust Corp now owns 25,556 shares of the biopharmaceutical company’s stock valued at $659,000 after buying an additional 12,178 shares in the last quarter. 70.05% of the stock is currently owned by institutional investors and hedge funds.
CBIO stock opened at $11.20 on Friday. The stock has a market cap of $129.58 million, a price-to-earnings ratio of -1.50 and a beta of 2.36. Catalyst Biosciences has a 52-week low of $4.49 and a 52-week high of $37.00.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Featured Story: What is Considered a Good Return on Equity (ROE)?
Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.